Table of Contents Author Guidelines Submit a Manuscript
International Journal of Chronic Diseases
Volume 2013 (2013), Article ID 578613, 15 pages
http://dx.doi.org/10.1155/2013/578613
Review Article

Biomarkers in Exhaled Breath Condensate and Serum of Chronic Obstructive Pulmonary Disease and Non-Small-Cell Lung Cancer

1Inflammation and Infection Research Centre, Faculty of Medicine, University of New South Wales, Sydney, NSW 2031, Australia
2Department of Respiratory Medicine, Prince of Wales Hospital, Randwick, Sydney, NSW 2031, Australia

Received 22 April 2013; Accepted 8 July 2013

Academic Editor: Jin-Yuan Shih

Copyright © 2013 Mann Ying Lim and Paul S. Thomas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. M. Adcock, G. Caramori, and P. J. Barnes, “Chronic Obstructive pulmonary disease and lung cancer: new molecular insights,” Respiration, vol. 81, no. 4, pp. 265–284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. K. F. Rabe, S. Hurd, A. Anzueto et al., “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 6, pp. 532–555, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. I. A. Yang, V. Relan, C. M. Wright et al., “Common pathogenic mechanisms and pathways in the development of COPD and lung cancer,” Expert Opinion on Therapeutic Targets, vol. 15, no. 4, pp. 439–456, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. WHO, “Chronic Obstructive Pulmonary Disease (COPD),” 2013, http://www.who.int/respiratory/copd/en/index.html.
  5. C. S. D. Cruz, L. T. Tanoue, and R. A. Matthay, “Lung cancer: epidemiology, etiology, and prevention,” Clinics in Chest Medicine, vol. 32, no. 4, pp. 605–644, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Siegel, E. Ward, O. Brawley, and A. Jemal, “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths,” CA Cancer Journal for Clinicians, vol. 61, no. 4, pp. 212–236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Young and R. J. Hopkins, “How the genetics of lung cancer may overlap with COPD,” Respirology, vol. 16, no. 7, pp. 1047–1055, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Dominioni, A. Imperatori, F. Rovera, A. Ochetti, G. Torrigiotti, and M. Paolucci, “Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening,” Cancer, vol. 89, no. 11, supplement, pp. 2334–2344, 2000. View at Google Scholar · View at Scopus
  9. A. Amann, M. Corradi, P. Mazzone, and A. Mutti, “Lung cancer biomarkers in exhaled breath,” Expert Review of Molecular Diagnostics, vol. 11, no. 2, pp. 207–217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. E. F. Patz, P. C. Goodman, and G. Bepler, “Screening for lung cancer,” The New England Journal of Medicine, vol. 343, no. 22, pp. 1627–1633, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Sone, T. Nakayama, T. Honda et al., “Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography,” Lung Cancer, vol. 58, no. 3, pp. 329–341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. D. R. Aberle, F. Abtin, and K. Brown, “Computed tomography screening for lung cancer: has it finally arrived? implications of the national lung screening trial,” Journal of Clinical Oncology, vol. 31, no. 8, pp. 1002–1008, 2013. View at Google Scholar
  13. L. Paleari, P. Granone, A. Cesario, and P. Russo, “Computed tomography screening for lung cancer: review of screening principles and update on current status,” Cancer, vol. 112, no. 11, pp. 2520–2521, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Senan, M. A. Paul, and F. J. Lagerwaard, “Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy?” The Lancet Oncology, vol. 14, no. 7, pp. e270–e274, 2013. View at Google Scholar
  15. C. I. Henschke, “Early lung cancer action project: overall design and findings from baseline screening,” Cancer, vol. 89, no. 11, supplement, pp. 2474–2482, 2000. View at Google Scholar · View at Scopus
  16. P. B. Bach, J. R. Jett, U. Pastorino, M. S. Tockman, S. J. Swensen, and C. B. Begg, “Computed tomography screening and lung cancer outcomes,” Journal of the American Medical Association, vol. 297, no. 9, pp. 953–961, 2007. View at Google Scholar
  17. D. M. Skillrud, K. P. Offord, and D. W. Miller, “Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study,” Annals of Internal Medicine, vol. 105, no. 4, pp. 503–507, 1986. View at Google Scholar · View at Scopus
  18. Y. Sekine, H. Katsura, E. Koh, K. Hiroshima, and T. Fujisawa, “Early detection of COPD is important for lung cancer surveillance,” European Respiratory Journal, vol. 39, no. 5, pp. 1230–1240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Yao and I. Rahman, “Current concepts on the role of inflammation in COPD and lung cancer,” Current Opinion in Pharmacology, vol. 9, no. 4, pp. 375–383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. S. Tockman, N. R. Anthonisen, and E. C. Wright, “Airways obstruction and the risk for lung cancer,” Annals of Internal Medicine, vol. 106, no. 4, pp. 512–518, 1987. View at Google Scholar · View at Scopus
  21. J. Koshiol, M. Rotunno, D. Consonni et al., “Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study,” PLoS One, vol. 4, no. 10, Article ID e7380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Turner, Y. Chen, D. Krewski, E. E. Calle, and M. J. Thun, “Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 3, pp. 285–290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. E. Mattson, E. S. Pollack, and J. W. Cullen, “What are the odds that smoking will kill you?” American Journal of Public Health, vol. 77, no. 4, pp. 425–431, 1987. View at Google Scholar · View at Scopus
  24. D. M. Mannino, S. M. Aguayo, T. L. Petty, and S. C. Redd, “Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up,” Archives of Internal Medicine, vol. 163, no. 12, pp. 1475–1480, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. S. Loganathan, D. E. Stover, W. Shi, and E. Venkatraman, “Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer,” Chest, vol. 129, no. 5, pp. 1305–1312, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Congleton and M. F. Muers, “The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy,” Respiratory Medicine, vol. 89, no. 4, pp. 291–296, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Papi, G. Casoni, G. Caramori et al., “COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma,” Thorax, vol. 59, no. 8, pp. 679–681, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. B. M. Smith, K. Schwartzman, B. Kovacina et al., “Lung cancer histologies associated with emphysema on computed tomography,” Lung Cancer, vol. 76, no. 1, pp. 61–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. P. J. Barnes, “Immunology of asthma and chronic obstructive pulmonary disease,” Nature Reviews Immunology, vol. 8, no. 3, pp. 183–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Punturieri, E. Szabo, T. L. Croxton, S. D. Shapiro, and S. M. Dubinett, “Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research,” Journal of the National Cancer Institute, vol. 101, no. 8, pp. 554–559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Nagorni-Obradović, D. Pesut, V. Skodrić-Trifunović, and T. Adzić, “Influence of tobacco smoke on the appearance of oxidative stress in patients with lung cancer and chronic obstructive pulmonary diseases,” Vojnosanitetski Pregled, vol. 63, no. 10, pp. 893–895, 2006. View at Google Scholar · View at Scopus
  32. I. Rahman and W. MacNee, “Role of oxidants/antioxidants in smoking-induced lung diseases,” Free Radical Biology and Medicine, vol. 21, no. 5, pp. 669–681, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. W. A. Pryor and K. Stone, “Oxidants in cigarette smoke: radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite,” Annals of the New York Academy of Sciences, vol. 686, pp. 12–28, 1993. View at Google Scholar · View at Scopus
  34. K. Kostikas, G. Papatheodorou, K. Psathakis, P. Panagou, and S. Loukides, “Oxidative stress in expired breath condensate of patients with COPD,” Chest, vol. 124, no. 4, pp. 1373–1380, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Louhelainen, M. Myllärniemi, I. Rahman, and V. L. Kinnula, “Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: current and future perspectives,” International Journal of COPD, vol. 3, no. 4, pp. 585–603, 2008. View at Google Scholar · View at Scopus
  36. C. A. Owen, “Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease,” Proceedings of the American Thoracic Society, vol. 2, no. 4, pp. 373–385, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Rahman, S. K. Biswas, and A. Kode, “Oxidant and antioxidant balance in the airways and airway diseases,” European Journal of Pharmacology, vol. 533, no. 1–3, pp. 222–239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Sauer, M. Wartenberg, and J. Hescheler, “Reactive oxygen species as intracellular messengers during cell growth and differentiation,” Cellular Physiology and Biochemistry, vol. 11, no. 4, pp. 173–186, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Garber, “A radical treatment,” Nature, vol. 489, no. 7417, pp. S4–S6, 2012. View at Google Scholar
  40. G. G. Brusselle, G. F. Joos, and K. R. Bracke, “New insights into the immunology of chronic obstructive pulmonary disease,” The Lancet, vol. 378, no. 9795, pp. 1015–1026, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Emmendoerffer, M. Hecht, T. Boeker, M. Mueller, and U. Heinrich, “Role of inflammation in chemical-induced lung cancer,” Toxicology Letters, vol. 112-113, pp. 185–191, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. E. A. Engels, “Inflammation in the development of lung cancer: epidemiological evidence,” Expert Review of Anticancer Therapy, vol. 8, no. 4, pp. 605–615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. S. D. Shapiro and E. P. Ingenito, “The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years,” American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 5, pp. 367–372, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Medzhitov, “Origin and physiological roles of inflammation,” Nature, vol. 454, no. 7203, pp. 428–435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. E. M. Drost, K. M. Skwarski, J. Sauleda et al., “Oxidative stress and airway inflammation in severe exacerbations of COPD,” Thorax, vol. 60, no. 4, pp. 293–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Federico, F. Morgillo, C. Tuccillo, F. Ciardiello, and C. Loguercio, “Chronic inflammation and oxidative stress in human carcinogenesis,” International Journal of Cancer, vol. 121, no. 11, pp. 2381–2386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Gessner, R. Scheibe, M. Wötzel et al., “Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 99, no. 10, pp. 1229–1240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. L. J. Marnett, “Oxyradicals and DNA damage,” Carcinogenesis, vol. 21, no. 3, pp. 361–370, 2000. View at Google Scholar · View at Scopus
  49. V. L. Kinnula, “Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases,” Thorax, vol. 60, no. 8, pp. 693–700, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. C. B. Gilks, K. Price, J. L. Wright, and A. Churg, “Antioxidant gene expression in rat lung after exposure to cigarette smoke,” American Journal of Pathology, vol. 152, no. 1, pp. 269–278, 1998. View at Google Scholar · View at Scopus
  51. K. McCusker and J. Hoidal, “Selective increase of antioxidant enzyme activity in the alveolar macrophages from cigarette smokers and smoke-exposed hamsters,” American Review of Respiratory Disease, vol. 141, no. 3, pp. 678–682, 1990. View at Google Scholar · View at Scopus
  52. I. Rahman and W. MacNee, “Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease,” Thorax, vol. 51, no. 4, pp. 348–350, 1996. View at Google Scholar · View at Scopus
  53. F. Balkwill and A. Mantovani, “Cancer and inflammation: implications for pharmacology and therapeutics,” Clinical Pharmacology and Therapeutics, vol. 87, no. 4, pp. 401–406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Porta, P. Larghi, M. Rimoldi et al., “Cellular and molecular pathways linking inflammation and cancer,” Immunobiology, vol. 214, no. 9-10, pp. 761–777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. D. I. Feig, T. M. Reid, and L. A. Loeb, “Reactive oxygen species in tumorigenesis,” Cancer Research, vol. 54, no. 7, supplement, pp. 1890s–1894s, 1994. View at Google Scholar · View at Scopus
  57. J. E. Klaunig and L. M. Kamendulis, “The role of oxidative stress in carcinogenesis,” Annual Review of Pharmacology and Toxicology, vol. 44, pp. 239–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Azad, Y. Rojanasakul, and V. Vallyathan, “Inflammation and lung cancer: roles of reactive oxygen/nitrogen species,” Journal of Toxicology and Environmental Health B, vol. 11, no. 1, pp. 1–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Szabó and H. Ohshima, “DNA damage induced by peroxynitrite: subsequent biological effects,” Nitric Oxide, vol. 1, no. 5, pp. 373–385, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. S. A. Belinsky, “Role of the cytosine DNA-methyltransferase and p16(INK4a) genes in the development of mouse lung tumors,” Experimental Lung Research, vol. 24, no. 4, pp. 463–479, 1998. View at Google Scholar · View at Scopus
  61. W. P. Bennett, T. V. Colby, W. D. Travis et al., “p53 Protein accumulates frequently in early bronchial neoplasia,” Cancer Research, vol. 53, no. 20, pp. 4817–4822, 1993. View at Google Scholar · View at Scopus
  62. S. S. Hecht, “Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention,” Lancet Oncology, vol. 3, no. 8, pp. 461–469, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Volm, G. Van Kaick, and J. Mattern, “Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases,” Clinical and Experimental Metastasis, vol. 12, no. 4, pp. 329–334, 1994. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Dubey and C. A. Powell, “Update in lung cancer 2007,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 9, pp. 941–946, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. S. S. Hecht, “Lung carcinogenesis by tobacco smoke,” International Journal of Cancer, vol. 131, no. 12, pp. 2724–2732, 2012. View at Google Scholar
  66. P. O'Reilly and W. Bailey, “Clinical use of exhaled biomarkers in COPD,” International Journal of COPD, vol. 2, no. 4, pp. 403–408, 2007. View at Google Scholar · View at Scopus
  67. G. M. Mutlu, K. W. Garey, R. A. Robbins, L. H. Danziger, and I. Rubinstein, “Collection and analysis of exhaled breath condensate in humans,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 5, pp. 731–737, 2001. View at Google Scholar · View at Scopus
  68. Z. L. Borrill, K. Roy, and D. Singh, “Exhaled breath condensate biomarkers in COPD,” European Respiratory Journal, vol. 32, no. 2, pp. 472–486, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. H. P. Chan, C. Lewis, and P. S. Thomas, “Exhaled breath analysis: novel approach for early detection of lung cancer,” Lung Cancer, vol. 63, no. 2, pp. 164–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. S. S. Y. Ai, K. Hsu, C. Herbert et al., “Mitochondrial DNA mutations in exhaled breath condensate of patients with lung cancer,” Respiratory Medicine, vol. 107, no. 6, pp. 911–918, 2013. View at Publisher · View at Google Scholar
  71. I. Horváth, J. Hunt, P. J. Barnes et al., “Exhaled breath condensate: methodological recommendations and unresolved questions,” European Respiratory Journal, vol. 26, no. 3, pp. 523–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. S. A. Kharitonov and P. J. Barnes, “Biomarkers of some pulmonary diseases in exhaled breath,” Biomarkers, vol. 7, no. 1, pp. 1–32, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. P. P. Rosias, C. M. Robroeks, H. J. Niemarkt et al., “Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate,” European Respiratory Journal, vol. 28, no. 5, pp. 1036–1041, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Baraldi, L. Ghiro, V. Piovan, S. Carraro, F. Zacchello, and S. Zanconato, “Safety and success of exhaled breath condensate collection in asthma,” Archives of Disease in Childhood, vol. 88, no. 4, pp. 358–360, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. I. Korovesi, E. Papadomichelakis, S. E. Orfanos et al., “Exhaled breath condensate in mechanically ventilated brain-injured patients with no lung injury or sepsis,” Anesthesiology, vol. 114, no. 5, pp. 1118–1129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. P. P. R. Rosias, C. M. Robroeks, K. D. van de Kant et al., “Feasibility of a new method to collect exhaled breath condensate in pre-school children,” Pediatric Allergy and Immunology, vol. 21, no. 1, pp. e235–244, 2010. View at Google Scholar · View at Scopus
  77. O. Holz, “Catching breath: monitoring airway inflammation using exhaled breath condensate,” European Respiratory Journal, vol. 26, no. 3, pp. 371–372, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Montuschi, “Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications,” Therapeutic Advances in Respiratory Disease, vol. 1, no. 1, pp. 5–23, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Montuschi, “Indirect monitoring of lung inflammation,” Nature Reviews Drug Discovery, vol. 1, no. 3, pp. 238–242, 2002. View at Google Scholar · View at Scopus
  80. R. M. Effros, M. B. Dunning III, J. Biller, and R. Shaker, “The promise and perils of exhaled breath condensates,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 287, no. 6, pp. L1073–L1080, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Liang, S. M. Yeligar, and L. A. S. Brown, “Exhaled breath condensate: a promising source for biomarkers of lung disease,” The Scientific World Journal, vol. 2012, Article ID 217518, 7 pages, 2012. View at Publisher · View at Google Scholar
  82. A. Bikov, G. Galffy, L. Tamasi, Z. Lazar, G. Losonczy, and I. Horvath, “Exhaled breath condensate pH is influenced by respiratory droplet dilution,” Journal of Breath Research, vol. 6, no. 4, Article ID 046002, 2012. View at Publisher · View at Google Scholar
  83. S. Chow, D. H. Yates, and P. S. Thomas, “Reproducibility of exhaled breath condensate markers,” European Respiratory Journal, vol. 32, no. 4, pp. 1124–1126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Okano, T. Kondo, T. Kakisaka et al., “Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis,” Proteomics, vol. 6, no. 13, pp. 3938–3948, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. W.-M. Gao, R. Kuick, R. P. Orchekowski et al., “Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis,” BMC Cancer, vol. 5, article 110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. A. M. Rodríguez-Piñeiro, S. Blanco-Prieto, N. Sánchez-Otero, F. J. Rodríguez-Berrocal, and M. P. de la Cadena, “On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion,” Journal of Proteomics, vol. 73, no. 8, pp. 1511–1522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. I. Salama, P. S. Malone, F. Mihaimeed, and J. L. Jones, “A review of the S100 proteins in cancer,” European Journal of Surgical Oncology, vol. 34, no. 4, pp. 357–364, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Vogl, A. L. Gharibyan, and L. A. Morozova-Roche, “Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes,” International Journal of Molecular Sciences, vol. 13, no. 3, pp. 2893–2917, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Hsu, C. Champaiboon, B. D. Guenther et al., “Anti-infective protective properties of S100 calgranulins,” Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, vol. 8, no. 4, pp. 290–305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. I. Marenholz, C. W. Heizmann, and G. Fritz, “S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature),” Biochemical and Biophysical Research Communications, vol. 322, no. 4, pp. 1111–1122, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Goyette and C. L. Geczy, “Inflammation-associated S100 proteins: new mechanisms that regulate function,” Amino Acids, vol. 41, no. 4, pp. 821–842, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. B. W. Schafer, R. Wicki, D. Engelkamp, M.-G. Mattei, and C. W. Heizmann, “Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family,” Genomics, vol. 25, no. 3, pp. 638–643, 1995. View at Publisher · View at Google Scholar · View at Scopus
  93. D. Foell, H. Wittkowski, T. Vogl, and J. Roth, “S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules,” Journal of Leukocyte Biology, vol. 81, no. 1, pp. 28–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. R. J. Passey, K. Xu, D. A. Hume, and C. L. Geczy, “S100A8: emerging functions and regulation,” Journal of Leukocyte Biology, vol. 66, no. 4, pp. 549–556, 1999. View at Google Scholar · View at Scopus
  95. C. Kerkhoff, M. Klempt, and C. Sorg, “Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9),” Biochimica et Biophysica Acta, vol. 1448, no. 2, pp. 200–211, 1998. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Roth, T. Vogl, C. Sorg, and C. Sunderkötter, “Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules,” Trends in Immunology, vol. 24, no. 4, pp. 155–158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. C. Gebhardt, J. Németh, P. Angel, and J. Hess, “S100A8 and S100A9 in inflammation and cancer,” Biochemical Pharmacology, vol. 72, no. 11, pp. 1622–1631, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Y. Lim, M. J. Raftery, and C. L. Geczy, “Oxidative modifications of DAMPs suppress inflammation: the case for S100A8 and S100A9,” Antioxidants and Redox Signaling, vol. 15, no. 8, pp. 2235–2248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. Y. L. Su, M. J. Raftery, J. Goyette, K. Hsu, and C. L. Geczy, “Oxidative modifications of S100 proteins: functional regulation by redox,” Journal of Leukocyte Biology, vol. 86, no. 3, pp. 577–587, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. P. Rouleau, K. Vandal, C. Ryckman et al., “The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis,” Clinical Immunology, vol. 107, no. 1, pp. 46–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Ryckman, K. Vandal, P. Rouleau, M. Talbot, and P. A. Tessier, “Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion,” Journal of Immunology, vol. 170, no. 6, pp. 3233–3242, 2003. View at Google Scholar · View at Scopus
  102. Z. Yang, T. Tao, M. J. Raftery, P. Youssef, N. Di Girolamo, and C. L. Geczy, “Proinflammatory properties of the human S100 protein S100A12,” Journal of Leukocyte Biology, vol. 69, no. 6, pp. 986–994, 2001. View at Google Scholar · View at Scopus
  103. M. A. Hofmann, S. Drury, C. Fu et al., “RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides,” Cell, vol. 97, no. 7, pp. 889–901, 1999. View at Publisher · View at Google Scholar · View at Scopus
  104. H.-L. Hsieh, B. W. Schäfer, N. Sasaki, and C. W. Heizmann, “Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays,” Biochemical and Biophysical Research Communications, vol. 307, no. 2, pp. 375–381, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. D. Foell and J. Roth, “Proinflammatory S100 proteins in arthritis and autoimmune disease,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 3762–3771, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. C. W. Heizmann, G. Fritz, and B. W. Schäfer, “S100 proteins: structure, functions and pathology,” Frontiers in Bioscience, vol. 7, pp. 1356–1368, 2002. View at Google Scholar · View at Scopus
  107. D. Foell, T. Kucharzik, M. Kraft et al., “Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease,” Gut, vol. 52, no. 6, pp. 847–853, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Merkel, W. Rist, P. Seither, A. Weith, and M. C. Lenter, “Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification,” Proteomics, vol. 5, no. 11, pp. 2972–2980, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. E. Lorenz, M. S. Muhlebach, P. A. Tessier et al., “Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases,” Respiratory Medicine, vol. 102, no. 4, pp. 567–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. G. Srikrishna, “S100A8 and S100A9: new insights into their roles in malignancy,” Journal of Innate Immunity, vol. 4, no. 1, pp. 31–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Vogl, C. Pröpper, M. Hartmann et al., “S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14,” Journal of Biological Chemistry, vol. 274, no. 36, pp. 25291–25296, 1999. View at Publisher · View at Google Scholar · View at Scopus
  112. G. Srikrishna and H. H. Freeze, “Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer,” Neoplasia, vol. 11, no. 7, pp. 615–628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. M. K. Srivastava, Å. Andersson, L. Zhu et al., “Myeloid suppressor cells and immune modulation in lung cancer,” Immunotherapy, vol. 4, no. 3, pp. 291–304, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. R. Donato, “S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles,” International Journal of Biochemistry and Cell Biology, vol. 33, no. 7, pp. 637–668, 2001. View at Publisher · View at Google Scholar · View at Scopus
  115. D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews Immunology, vol. 9, no. 3, pp. 162–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. P. H. Feng, K. Y. Lee, Y. L. Chang et al., “CD14+S100A9+ monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer,” American Journal of Respiratory & Critical Care Medicine, vol. 186, no. 10, pp. 1025–1036, 2012. View at Google Scholar
  117. P. Sinha, C. Okoro, D. Foell, H. H. Freeze, S. Ostrand-Rosenberg, and G. Srikrishna, “Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells,” Journal of Immunology, vol. 181, no. 7, pp. 4666–4675, 2008. View at Google Scholar · View at Scopus
  118. S. Nagaraj and D. I. Gabrilovich, “Myeloid-derived suppressor cells in human cancer,” Cancer Journal, vol. 16, no. 4, pp. 348–353, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Dolcetti, I. Marigo, B. Mantelli, E. Peranzoni, P. Zanovello, and V. Bronte, “Myeloid-derived suppressor cell role in tumor-related inflammation,” Cancer Letters, vol. 267, no. 2, pp. 216–225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Serafini, I. Borrello, and V. Bronte, “Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression,” Seminars in Cancer Biology, vol. 16, no. 1, pp. 53–65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. S. Ostrand-Rosenberg, “Cancer and complement,” Nature Biotechnology, vol. 26, no. 12, pp. 1348–1349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. G. Zwadlo, J. Bruggen, G. Gerhards, R. Schlegel, and C. Sorg, “Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues,” Clinical and Experimental Immunology, vol. 72, no. 3, pp. 510–515, 1988. View at Google Scholar · View at Scopus
  123. K. Odink, N. Cerletti, J. Bruggen et al., “Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis,” Nature, vol. 330, no. 6143, pp. 80–82, 1987. View at Google Scholar · View at Scopus
  124. A. Hermani, B. De Servi, S. Medunjanin, P. A. Tessier, and D. Mayer, “S100A8 and S100A9 activate MAP kinase and NF-κB signaling pathways and trigger translocation of RAGE in human prostate cancer cells,” Experimental Cell Research, vol. 312, no. 2, pp. 184–197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Hermani, J. Hess, B. De Servi et al., “Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer,” Clinical Cancer Research, vol. 11, no. 14, pp. 5146–5152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. H.-Y. Yong and A. Moon, “Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells,” Archives of Pharmacal Research, vol. 30, no. 1, pp. 75–81, 2007. View at Google Scholar · View at Scopus
  127. J. Stuli'k, J. Osterreicher, K. Koupilova' et al., “The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass,” Electrophoresis, vol. 20, no. 4-5, pp. 41047–41554, 1999. View at Google Scholar
  128. H.-J. Kim, H. J. Kang, H. Lee et al., “Identification of S100A8 and S100A9 as serological markers for colorectal cancer,” Journal of Proteome Research, vol. 8, no. 3, pp. 1368–1379, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. H. Kawai, Y. Minamiya, and N. Takahashi, “Prognostic impact of S100A9 overexpression in non-small cell lung cancer,” Tumor Biology, vol. 32, no. 4, pp. 641–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. K. Arai, “Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation,” Oncology Reports, vol. 8, no. 3, pp. 591–596, 2001. View at Google Scholar · View at Scopus
  131. S. Rafii and D. Lyden, “S100 chemokines mediate bookmarking of premetastatic niches,” Nature Cell Biology, vol. 8, no. 12, pp. 1321–1323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. S. Hiratsuka, A. Watanabe, H. Aburatani, and Y. Maru, “Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis,” Nature Cell Biology, vol. 8, no. 12, pp. 1369–1375, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Hiratsuka, A. Watanabe, Y. Sakurai et al., “The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase,” Nature Cell Biology, vol. 10, no. 11, pp. 1349–1355, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Kwiatkowska, K. Noweta, M. Zieba, D. Nowak, and P. Bialasiewicz, “Enhanced exhalation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with COPD exacerbation: a prospective study,” Respiration, vol. 84, no. 3, pp. 231–241, 2012. View at Publisher · View at Google Scholar
  135. H. P. Chan, V. Tran, C. Lewis, and P. S. Thomas, “Elevated levels of oxidative stress markers in exhaled breath condensate,” Journal of Thoracic Oncology, vol. 4, no. 2, pp. 172–178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. P. N. R. Dekhuijzen, K. K. H. Aben, I. Dekker et al., “Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 3, pp. 813–816, 1996. View at Google Scholar · View at Scopus
  137. H. Inonu, S. Doruk, S. Sahin et al., “Oxidative stress levels in exhaled breath condensate associated with COPD and smoking,” Respiratory Care, vol. 57, no. 3, pp. 413–419, 2012. View at Publisher · View at Google Scholar · View at Scopus
  138. D. Nowak, M. Kasielski, A. Antczak, T. Pietras, and P. Bialasiewicz, “Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking,” Respiratory Medicine, vol. 93, no. 6, pp. 389–396, 1999. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Corradi, M. Majori, G. C. Cacciani, G. F. Consigli, E. De'Munari, and A. Pesci, “Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease,” Thorax, vol. 54, no. 7, pp. 572–575, 1999. View at Google Scholar · View at Scopus
  140. C.-Y. Liu, C.-H. Wang, T.-C. Chen, H.-C. Lin, C.-T. Yu, and H.-P. Kuo, “Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer,” British Journal of Cancer, vol. 78, no. 4, pp. 534–541, 1998. View at Google Scholar · View at Scopus
  141. J. Liu, A. Sandrini, M. C. Thurston, D. H. Yates, and P. S. Thomas, “Nitric oxide and exhaled breath nitrite/nitrates in chronic obstructive pulmonary disease patients,” Respiration, vol. 74, no. 6, pp. 617–623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. F. A. Masri, S. A. A. Comhair, T. Koeck et al., “Abnormalities in nitric oxide and its derivatives in lung cancer,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 5, pp. 597–605, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. W. Maziak, S. Loukides, S. Culpitt, P. Sullivan, S. A. Kharitonov, and P. J. Barnes, “Exhaled nitric oxide in chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 3, pp. 998–1002, 1998. View at Google Scholar · View at Scopus
  144. P. Montuschi, S. A. Kharitonov, and P. J. Barnes, “Exhaled carbon monoxide and nitric oxide in COPD,” Chest, vol. 120, no. 2, pp. 496–501, 2001. View at Publisher · View at Google Scholar · View at Scopus
  145. C. Gessner, S. Hammerschmidt, H. Kuhn et al., “Breath condensate nitrite correlates with hyperinflation in chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 101, no. 11, pp. 2271–2278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  146. V. Rihák, P. Zatloukal, J. Chládková, A. Zimulová, Z. Havlínová, and J. Chládek, “Nitrite in exhaled breath condensate as a marker of nitrossative stress in the airways of patients with asthma, COPD, and idiopathic pulmonary fibrosis,” Journal of Clinical Laboratory Analysis, vol. 24, no. 5, pp. 317–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. M. Corradi, A. Pesci, R. Casana et al., “Nitrate in exhaled breath condensate of patients with different airway diseases,” Nitric Oxide, vol. 8, no. 1, pp. 26–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  148. C. Brindicci, K. Ito, O. Torre, P. J. Barnes, and S. A. Kharitonov, “Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients,” Chest, vol. 135, no. 2, pp. 353–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. G. O. Osoata, T. Hanazawa, C. Brindicci et al., “Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine,” Chest, vol. 135, no. 6, pp. 1513–1520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. P. Montuschi, J. V. Collins, G. Ciabattoni et al., “Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 3, pp. 1175–1177, 2000. View at Google Scholar · View at Scopus
  151. F. W. S. Ko, C. Y. K. Lau, T. F. Leung, G. W. K. Wong, C. W. K. Lam, and D. S. C. Hui, “Exhaled breath condensate levels of 8-isoprostane, growth related oncogene α and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 100, no. 4, pp. 630–638, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. E. Dalaveris, T. Kerenidi, A. Katsabeki-Katsafli et al., “VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer,” Lung Cancer, vol. 64, no. 2, pp. 219–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  153. M. Corradi, I. Rubinstein, R. Andreoli et al., “Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 10, pp. 1380–1386, 2003. View at Publisher · View at Google Scholar · View at Scopus
  154. A. Gönenç, Y. Özkan, M. Torun, and B. Şmşek, “Plasma malondialdehyde (MDA) levels in breast and lung cancer patients,” Journal of Clinical Pharmacy and Therapeutics, vol. 26, no. 2, pp. 141–144, 2001. View at Publisher · View at Google Scholar · View at Scopus
  155. H. Ahmadzai, S. Huang, R. Hettiarachchi, J. L. Lin, P. S. Thomas, and Q. Zhang, “Exhaled breath condensate: a comprehensive update,” Clinical Chemistry and Laboratory Medicine, pp. 1343–1361, 2013. View at Publisher · View at Google Scholar
  156. G. E. Carpagnano, G. P. Palladino, D. Lacedonia, A. Koutelou, S. Orlando, and M. P. Foschino-Barbaro, “Neutrophilic airways inflammation in lung cancer: the role of exhaled LTB-4 and IL-8,” BMC Cancer, vol. 11, article 226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  157. J.-L. Corhay, M. Henket, D. Nguyen, B. Duysinx, J. Sele, and R. Louis, “Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD,” Chest, vol. 136, no. 4, pp. 1047–1054, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. P. Montuschi, S. A. Kharitonov, G. Ciabattoni, and P. J. Barnes, “Exhaled leukotrienes and prostaglandins in COPD,” Thorax, vol. 58, no. 7, pp. 585–588, 2003. View at Publisher · View at Google Scholar · View at Scopus
  159. K. Kostikas, M. Gaga, G. Papatheodorou, T. Karamanis, D. Orphanidou, and S. Loukides, “Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma,” Chest, vol. 127, no. 5, pp. 1553–1559, 2005. View at Publisher · View at Google Scholar · View at Scopus
  160. A. Antczak, W. Piotrowski, J. Marczak, M. Ciebiada, P. Gorski, and P. J. Barnes, “Correlation between eicosanoids in bronchoalveolar lavage fluid and in exhaled breath condensate,” Disease Markers, vol. 30, no. 5, pp. 213–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. E. Chan, T. Sivagnanam, Q. Zhang, C. R. Lewis, and P. S. Thomas, “Tumour necrosis factor alpha and oxidative stress in the breath condensate of those with non-small cell lung cancer,” Journal of Cancer Therapy, vol. 3, no. 4A, pp. 460–466, 2012. View at Publisher · View at Google Scholar
  162. E. Bucchioni, S. A. Kharitonov, L. Allegra, and P. J. Barnes, “High levels of interleukin-6 in the exhaled breath condensate of patients with COPD,” Respiratory Medicine, vol. 97, no. 12, pp. 1299–1302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  163. G. E. Carpagnano, O. Resta, M. P. Foschino-Barbaro, E. Gramiccioni, and F. Carpagnano, “Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer,” International Journal of Biological Markers, vol. 17, no. 2, pp. 141–145, 2002. View at Google Scholar · View at Scopus
  164. A.-R. Koczulla, S. Noeske, C. Herr et al., “Acute and chronic effects of smoking on inflammation markers in exhaled breath condensate in current smokers,” Respiration, vol. 79, no. 1, pp. 61–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. G. E. Carpagnano, G. P. Palladino, D. Martinelli, D. Lacedonia, S. Orlando, and M. P. Foschino-Barbaro, “Exhaled matrix metalloproteinase-9 in lung cancer,” Rejuvenation Research, vol. 15, no. 4, pp. 359–365, 2012. View at Publisher · View at Google Scholar
  166. P. Carratu, C. Scoditti, M. Maniscalco et al., “Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension,” BMC Pulmonary Medicine, vol. 8, article 20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. G. E. Carpagnano, M. P. Foschino-Barbaro, O. Restaa, E. Gramiccioni, and F. Carpagnano, “Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer,” Oncology, vol. 66, no. 3, pp. 180–184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  168. L. Chen, H.-L. Zhu, and X. Zhang, “Clinical significance of measuring endothelin-1 in exhaled breath condensate of patients with non-small cell lung cancer,” Journal of Xi'an Jiaotong University, vol. 32, no. 4, pp. 458–461, 2011. View at Google Scholar · View at Scopus
  169. P. Paredi, S. A. Kharitonov, D. Leak, S. Ward, D. Cramer, and P. J. Barnes, “Exhaled ethane, a marker of lipid peroxidation, is elevated chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 2, pp. 369–373, 2000. View at Google Scholar · View at Scopus
  170. M. Phillips, K. Gleeson, J. M. B. Hughes et al., “Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study,” Lancet, vol. 353, no. 9168, pp. 1930–1933, 1999. View at Publisher · View at Google Scholar · View at Scopus
  171. G. Song, T. Qin, H. Liu et al., “Quantitative breath analysis of volatile organic compounds of lung cancer patients,” Lung Cancer, vol. 67, no. 2, pp. 227–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. B. Antus and I. Barta, “Exhaled breath condensate pH in patients with lung cancer,” Lung Cancer, vol. 75, no. 2, pp. 178–180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  173. W. MacNee, S. I. Rennard, J. F. Hunt et al., “Evaluation of exhaled breath condensate pH as a biomarker for COPD,” Respiratory Medicine, vol. 105, no. 7, pp. 1037–1045, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. K. Kostikas, G. Papatheodorou, K. Ganas, K. Psathakis, P. Panagou, and S. Loukides, “pH in expired breath condensate of patients with inflammatory airway diseases,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 10, pp. 1364–1370, 2002. View at Publisher · View at Google Scholar · View at Scopus
  175. W. Lee, H. Loo, and P. S. Thomas, “Airway antioxidant capacity and pH in chronic obstructive pulmonary disease,” Oxidants and Antioxidants in Medical Science, vol. 1, no. 3, pp. 153–160, 2012. View at Google Scholar
  176. G. E. Carpagnano, M. P. Foschino-Barbaro, G. Mulé et al., “3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 6, pp. 738–744, 2005. View at Publisher · View at Google Scholar · View at Scopus
  177. C. Gessner, H. Kuhn, K. Toepfer, S. Hammerschmidt, J. Schauer, and H. Wirtz, “Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients,” Lung Cancer, vol. 43, no. 2, pp. 215–222, 2004. View at Publisher · View at Google Scholar · View at Scopus
  178. C. Gessner, “Nachweis von mutationen des K-ras-Cens im atemkondensat von patienten mit nicht-kleinzelligem lungenkarzinom (NSCLC) als mögliche nicht-invasive screeningmethode,” Pneumologie, vol. 52, no. 7, pp. 426–427, 1998. View at Google Scholar · View at Scopus
  179. D. Zhang, N. Takigawa, N. Ochi et al., “Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung,” Lung Cancer, vol. 73, no. 3, pp. 379–380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  180. W. Han, T. Wang, A. A. Reilly, S. M. Keller, and S. D. Spivack, “Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients,” Respiratory Research, vol. 10, article 86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  181. G. E. Carpagnano, A. Koutelou, M. I. Natalicchio et al., “HPV in exhaled breath condensate of lung cancer patients,” British Journal of Cancer, vol. 105, no. 8, pp. 1183–1190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  182. G. E. Carpagnano, D. Lacedonia, G. P. Palladino et al., “Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes?” European Journal of Clinical Investigation, vol. 42, no. 5, pp. 478–486, 2012. View at Publisher · View at Google Scholar · View at Scopus